This article was originally published in The Gray Sheet
Imminent spin-off of the orthopedic firm's competitor Zimmer from parent company Bristol Myers Squibb will help solidify pricing in the orthopedic market, the firm maintains. As a public entity accountable to investors, Zimmer would be less likely to implement discount pricing, a strategy used when it was part of the larger BMS pharmaceutical firm, Stryker says
You may also be interested in...
COVID-19 Vaccines: ACIP’s Allocation Proposal Prioritizes Long-Term Care Residents, Essential Workers
First group to receive vaccine would comprise health care personnel and residents of long-term care facilities; next in line are non-health care essential workers, who would take priority over adults with high-risk medical conditions and those ages 65 years and older, according to the CDC advisory committee’s proposed allocation framework.
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.
Sanofi R&D head John Reed says the company has kept 95% of patients on its nearly 400 clinical trials, started 59 studies, and benefited from its in-house drug supply management.